SEARCH

SEARCH BY CITATION

References

  • 1
    Kakizoe T. Prostate carcinoma. In: Johnson FE, Virgo KS, eds. Cancer Patients Follow-Up. Mosby-Year Book, St Louis, 1997; 395400.
  • 2
    Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J. Urol. 1999; 162: 133740.
  • 3
    Partin AW, Pearson JD, Landis PK et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 64959.
  • 4
    Joseph OH, John WC, David K et al. Current follow up strategies after radical prostatectomy: A survey of American Urological Association Urologists. J. Uorl 1999; 161: 5203.
  • 5
    Huben RP. Prostate carcinoma. In: Johnson FE, Virgo KS, eds. Cancer Patients Follow-Up. Mosby-Year Book, St Louis, 1997; 37889.
  • 6
    Zinke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of prostate: Significant influences of immediate adjuvant hormonal treatment on outcome. Urology 1989; 33: 2736.
  • 7
    Akimoto S, Akakura K, Ohki T et al. [Usefulness of hyper sensitive PSA assay kits for determination on low range of prostate specific antigen in prostate cancer.] Jpn. J. Urol 1995; 86: 25662 (in Japanese).
  • 8
    Nodate K, Tukada T. [Evaluation of chemiluminescent enzyme immunoassay ‘Lumipulse PSA’.] Jpn. J. Medical Pharm. Sci. 1996; 36: 1395402 (in Japanese).
  • 9
    Leo ME, Bilhartz DL, Bergstralh EJ, Oesterling JE. Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J. Urol. 1991; 145: 8026.
  • 10
    Sobin LH, Wikind Ch(eds). ULCC TNM Classification of Malignant Tumors, 5th Edition, A John Wiley & Sons, 1997; 1703.
  • 11
    Egawa S, Matsumoto K, Suyama K, Iwamura M, Kuwao S, Baba S. Observations of prostate specific antigen doubling time in Japanese patient with nonmetastatic prostate carcinoma. Cancer 1999; 86: 4639.
  • 12
    Stamey TA, Graves HCB, Wehner N, Ferrari M, Freiha FS. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J. Urol. 1993; 149: 78792.
  • 13
    Bhayani SB, Andriole GL. Hormonal manipulation for rising PSA after radical prostatectomy. Semin. Urol. Oncol. 1999; 17: 14853.
  • 14
    Ruffion A, Valignat C, Champetier D, Lopez JG, Perrin P. Observation / delayed treatment for rising PSA after radical prostatectomy. Pros Cons. Semin. Urol. Oncol. 1999; 17: 13540.
  • 15
    McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J. Urol. 1994; 152: 178691.
  • 16
    Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J. Urol. 1998; 159: 35764.
  • 17
    Valicenti RK, Gomella LG, Ismail M et al. Durable efficacy of early postoperative radiation therapy for high-risk pT3N0 prostate cancer: The importance of radiation dose. Urology 1998; 52: 103440.DOI: 10.1016/S0090-4295(98)00405-1
  • 18
    D’Amico AV, Whittington R, Malkowicz SB et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J. Urol. 1998; 160: 2096101.
  • 19
    D’Amico AV, Desjardin A, Chung A et al. Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 1998; 82: 188796.
  • 20
    Trapasso JG, DeKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J. Urol. 1994; 152: 18215.
  • 21
    Oefelein MG, Smith N, Carter M, Dalton D, Schaeffer A. The incidence of prostate cancer progression with undetectable serum prostate specific antigen in a series of 394 radical prostatectomies. J. Urol. 1995; 154: 212831.
  • 22
    Rabbani F, Perrotti M, Baster A, Fair WR. Prostate specific antigen doubling time after radical prostatectomy. Effect of Neoadjuvant androgen deprivation therapy. J. Urol. 1999; 161: 84752.